Our Science

Platform Collaborators

UM

 

National Institutes of Health
NIH/NINDS HEAL UH3 Award

Award to Support All Formal CMC and Pre-Clinical GLP/GMP/GCP Development Work Through a First-in-Human Study in Patients with Moderate to Severe Chronic Knee Pain Due to Osteoarthritis Pain.

 

University of Miami

Exclusive License Agreement for Patents Protecting Non-Enzymatic Carbonic Anhydrase DNA Constructs, Their Protein Products, Gene Therapies and Uses Managing Pain.

 

University of Pittsburgh

Exclusive License Agreement for Patents Protecting Non-Toxic Replication-Defective HSV Vectors for Efficient Gene Delivery Applications and Complementing Cells for Their Production.

 

 

National Institutes of Health
NIH/NINDS HEAL UH3 Award

Award to Support All Formal CMC and Pre-Clinical GLP/GMP/GCP Development Work Through a First-in-Human Study in Patients with Moderate to Severe Chronic Knee Pain Due to Osteoarthritis Pain.

 

 

University of Miami

Exclusive License Agreement for Patents Protecting Non-Enzymatic Carbonic Anhydrase DNA Constructs, Their Protein Products, Gene Therapies and Uses Managing Pain.

 

 

 

University of Pittsburg

Exclusive License Agreement for Patents Protecting Non-Toxic Replication-Defective HSV Vectors for Efficient Gene Delivery Applications and Complementing Cells for Their Production.

 

Market Exclusivity Drivers

*Typical Patent Expiry upon grant is 20 years from priority date, excluding any patent term extensions or other term adjustments

MARKET
EXCLUSIVITY

7 years Orphan exclusivity from approval in US

10 years market
exclusivity from
approval in Europe

12 years biological
exclusivity from
approval in US

Gene Therapy Technology

Pipeline

Scientific Publications